Reframe (Glucobit)

joinreframeapp.com →

-81%

est. 2Y upside i

HealthcareSeries A

App to help people quit or cut back on alcohol use

Rank

#3921

Sector

Consumer Health and Wellness

Est. Liquidity

~4Y

Data Quality

Data: Medium

Reframe (Glucobit) presents a risky equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (15%)+260%

Reframe accelerates its ARR growth to 30% YoY by expanding its B2B corporate wellness offerings and enhancing its AI-driven personalization, reaching $23M ARR in two years. This improved performance, coupled with a strong market for digital health solutions, could justify a 7x ARR multiple, leading to a $160M valuation (2.9x current estimated valuation of $55M).

Base (35%)+18%

Reframe maintains its position in the mindful drinking niche, growing ARR at 10-15% YoY to approximately $16M in two years. It continues to differentiate with its neuroscience-backed program but faces steady competition. A modest 4x ARR multiple would result in a $64M valuation, offering limited upside for common shareholders.

Bear (50%)-90%

Aggressive expansion of GLP-1 medications into alcohol use disorder treatment by pharmaceutical incumbents like Eli Lilly and Novo Nordisk significantly impacts Reframe's user acquisition and retention, causing ARR to stagnate or decline to $12M. A compressed 2x ARR multiple would lead to a $24M valuation, resulting in a near-total loss for common shareholders due to the $19M liquidation preference.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Investors have provided $19M in funding. At an estimated current valuation of $55M, this represents 34.5% of the company's value, meaning investors would take $19M before common shareholders see returns in a liquidation event at or below current valuation.

Dilution Risk

high

With low growth and $19M raised, the company will likely need to raise additional funding rounds (Series B, C) within the next 2-4 years, which will dilute existing equity holders.

Secondary Liquidity

none

As a Series A company, there is no active secondary market for employee shares or tender offers.

Other — 1 role

View all 1 open roles at Reframe (Glucobit) →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Reframe (Glucobit)'s data — designed to show you've done your homework.

  • 1

    “With pharmaceutical giants like Eli Lilly and Novo Nordisk advancing GLP-1s for alcohol use disorder, how does Reframe plan to maintain its competitive edge and differentiate its digital-first approach against these powerful new treatment modalities?”

  • 2

    “Given the current 9% YoY growth rate, which is relatively low for a Series A digital health company, what are the specific strategies and initiatives planned over the next 12-24 months to significantly accelerate ARR growth and improve unit economics?”

  • 3

    “Considering the company's Series A funding and the current market conditions, what is the anticipated timeline for a liquidity event, and how does the company plan to manage potential dilution for common stock holders in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -81% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.